![Mass Device](https://www.dayzerodiagnostics.com/wp-content/uploads/2020/09/massdevice_logo.png)
Day Zero Diagnostics Wins $6.2M From Accelerator
May 12 2020
CARB-X award to fund DZD’s new technology to rapidly identify pathogens and determine their drug resistance profile
Read More![](https://www.dayzerodiagnostics.com/wp-content/uploads/2020/09/360dx_logo-e1600704864688.png)
DZD Using CARB-X Award to Commercialize Antibiotic-Resistance Testing Platform
May 11 2020
360Dx reporter John Gilmore covers DZD’s plans to advance new diagnostic system with CARB-X funding
Read More![](https://www.dayzerodiagnostics.com/wp-content/uploads/2020/09/carbx_logo-e1600704799944.png)
CARB-X Awards DZD $6.2M to Develop New Test To Diagnose Deadly Superbug Infections
May 11 2020
Funding award is the first whole genome sequencing and machine learning technology in CARB-X portfolio
Read More![](https://www.dayzerodiagnostics.com/wp-content/uploads/2020/02/nyt_full-e1600704754808.jpg)
New Genomic Tests Aim to Diagnose Deadly Infections Faster
February 24 2020
DZD included in the new class of diagnostics for infectious diseases
Read More![](https://www.dayzerodiagnostics.com/wp-content/uploads/2020/09/wsjpro-e1605106960554.png)
Diagnostic Startups Take on Growing Threat of Antibiotic-Resistant Bugs
January 14 2020
DZD featured in WSJ review of emerging diagnostic companies
Read More![](https://www.dayzerodiagnostics.com/wp-content/uploads/2020/09/genomeweb_logo-e1600703810114.png)
Genomics Links Fecal Transplant Recipient Infections to Drug-Resistant E. coli Donor
October 31 2019
EpiXact uses sequencing to confirm cause of patient death in a clinical trial with wide ranging implications
Read More